Authors
Latest:
Dr. Martin on the Utility of CAR T-Cell Therapy in High-Risk MCLPeter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.
Latest:
Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCLReem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Sasine on Predicting Individual Benefit with CAR T CellsJoshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.
Latest:
Emerging CAR T-Cell Therapies in Hematologic CancersXiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.
Latest:
Dr. Hammers on Challenges With CAR T-Cell Therapy in RCCHans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.
Latest:
Dr. Frey on CAR T-Cell Therapy in High-Risk ALLNoelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.
Latest:
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple MyelomaDavid E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.
Latest:
John DiPersio, MD, PhD, on Ongoing Advancements in Stem Cell Transplantation and Cell TherapyThe director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine discussed novel innovations that lie on the horizon.
Latest:
Dr. Mato on Utilizing CAR T Cells in CLLAnthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.
Latest:
Cohort Data From TRANSCEND-CLL-004 of Liso-Cel: William G. Wierda, MDThe associate professor of medicine from MD Anderson Cancer Center discussed data from the phase 1 cohort of liso-cel combined with ibrutinib.
Latest:
Dr. Siddiqi on the Rationale to Evaluate CAR T-Cell Therapy in CLLTanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.
Latest:
Sham Mailankody, MBBS, on Further Research With ALLO-715The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.
Latest:
Dr. Rule on Potential for CAR T-Cell Therapy in MCLSimon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.
Latest:
Dr. Wong on Investigational CAR T-Cell Products in Multiple MyelomaSandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.
Latest:
Dr. Ramakrishnan on Use of CAR T-Cell Therapy in MCLPraveen Ramakrishnan, MD, discusses CAR T-cell therapy in patients with mantle cell lymphoma (MCL).
Latest:
Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple MyelomaParameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Latest:
Unmet Needs and Management in Multiple Myeloma: Peter Voorhees, MDThe hematologist/oncologist discussed unmet needs and novel therapies in multiple myeloma and give practical advice for community oncologists.
Latest:
Andrea Price, APN, Discusses Electronic Medical Records in CAR T-Cell TherapyThe associate director for clinical research at the Washington University School of Medicine spoke about the value and challenges of using EMRs in CAR T-cell therapy.
Latest:
Advantages of Off-the-Shelf CAR NK Therapy in B-Cell MalignanciesBob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.
Latest:
Dr. Gauthier on Potential for CAR T Cells in CLLJordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.
Latest:
Dr. Goy on Next Steps With CAR T-Cell Therapy in MCLAndre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALLChing-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.
Latest:
Dr. Jain on Hematopoietic Recovery Following CAR T-Cell TherapyTania Jain, MBBS, discusses hematopoietic recovering following treatment with a chimeric antigen receptor T-cell therapy in patients with hematologic malignancies.
Latest:
Dr. Adusumilli on the Development of CAR T Cells in Solid TumorsPrasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.
Latest:
The Future of Frontline CAR T in Mantle Cell Lymphoma: Brad S. Kahl, MDThe professor of medicine at Washington University School of Medicine in St. Louis discussed the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma.
Latest:
Further Research With Tab-Cel in EBV+ Post-Transplant Lymphoproliferative DiseaseAJ Joshi, MD, chief medical officer, Atara Biotherapeutics, discussed further research with tab-cel, including study 205.
Latest:
Nausheen Ahmed, MD, on the Impact of Prior Treatments on the Safety of Brexu-celThe assistant professor in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center discussed real-world safety outcomes for brexu-cel in patients with r/r MCL.
Latest:
Keys to a Successful Cell and Gene Therapy LaunchThe success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.
Latest:
Adrian Kilcoyne, MD, MPH, MBA, on Adjusting Expectations for Remission Rates in Non–CAR-T Cell Therapy TrialsThe chief medical officer of Cellularity discussed the big picture implications of a new analysis of patient samples from legacy studies evaluating MLASC therapy in Crohn disease.
Latest:
Next Steps With CAR T-Cell Therapy in Multiple Myeloma: Omar Castaneda Puglianini, MDThe hematologist and medical oncologist discussed next steps with CAR T-cell therapy in penta-refractory multiple myeloma.
